Perspectives on HER2-Positive Breast Cancer - priME Oncology
Expert Perspectives
Expert Perspectives

Perspectives on HER2-Positive Breast Cancer

A Personalized Approach to Treatment

View Activity

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

View expert faculty discuss highlights from their presentations and downloadable slides from HER2-Positive Breast Cancer: A Personalized Approach to Treatment, held at the European Oncology Meeting in Barcelona. Faculty discuss the biology of HER2-positive breast cancer, the role of neoadjuvant therapy for HER2-positive early breast cancer, and risk-adapted treatments for HER2-positive early breast cancer.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Nov 8, 2019

Expiration Date

Nov 8, 2020

  • Javier Cortés, MD, PhDIOB Institute of Oncology, Madrid and Barcelona
    Vall d'Hebron Institute of Oncology (VHIO)
    Medica Scientia Innovation Research (MedSIR)
    Barcelona, Spain
  • Sara Hurvitz, MD, FACPUniversity of California, Los Angeles
    UCLA Jonsson Comprehensive Cancer Center
    Los Angeles, California, United States
  • Sibylle Loibl, MD, PhDGerman Breast Group, Neu-Isenburg
    Centre for Haematology and Oncology Bethanien
    Frankfurt, Germany
  • Martine Piccart, MD, PhDJules Bordet Institute
    Brussels, Belgium

Introduction
Martine Piccart, MD, PhD

Getting to grips with the biology of HER2-positive breast cancer
Sara Hurvitz, MD, FACP

Neoadjuvant treatment strategies for HER2-positive early breast cancer: Should treatment recommendations be response-based?
Sibylle Loibl, MD, PhD

Risk-adapted treatments for HER2-positive early breast cancer
Javier Cortés, MD, PhD

This educational activity is designed for oncologists, gynecologists, breast surgeons, and other healthcare professionals who are interested in and/or involved in the treatment of breast cancer and wish to understand how to apply some of the latest developments in treatments for HER2-positive early breast cancer into routine clinical practice.

After successful completion of this educational activity, participants should be able to:

  • Describe the interactions of HER2 signaling with other biologic and immunologic pathways
  • Select the optimal HER2-targeted strategy to improve long-term disease endpoints in patients with HER2-positive early breast cancer
  • Define a risk adapted approach for when to either de-escalate or intensify HER2 targeted treatments

This educational activity is supported by a grant from F. Hoffmann-La Roche Ltd.

Independent Medical Education

This IME activity is organized by prIME, a Medscape Oncology Company. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME, a Medscape Oncology Company.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME, a Medscape Oncology Company requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved by prIME, a Medscape Oncology. prIME, a Medscape Oncology  is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Chair

Disclosure: Martine Piccart, MD, PhD, has disclosed the following relevant financial relationships:

  • Served as consultant (honoraria) for: AstraZeneca; Camel-IDS; Crescendo Biologics; Debiopharm; GI Therapeutics; Genentech, Inc.; Huya; Immunomedics; Lilly; Menarini; Merck Sharpe & Dohme; Novartis Pharmaceuticals Corporation; Odonate; Oncolytics; Periphagen; Pfizer Inc.; Roche; Seattle Genetics
  • Received research grants to my institute from: AstraZeneca; Lilly; Merck Sharpe & Dohme; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Radius; Roche-Genentech, Inc.; SERVIER; Synthon
  • Served as board member (Scientific Board) for: Oncolytics; Radius

Faculty

Disclosure: Javier Cortés, MD, PhD, has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: AstraZeneca; Athenex; Biothera Pharmaceutical; Celgene Corporation; Cellestia; Daiichi Sankyo, Inc.; Erytech; GlaxoSmithKline; Lilly; Merck Sharpe & Dohme; Merus; Polyphor; Roche; Seattle Genetics, Inc.; SERVIER
  • Received grants for clinical research from: Ariad pharmaceuticals; AstraZeneca; Baxalta GMBH/Servier Affaires; Bayer healthcare; Eisai; F. Hoffman-La Roche; Guardant health; Merck Sharp & Dohme, Pfizer; Piqur Therapeutics; Puma; Seattle Genetics; Queen Mary University of London
  • Received honoraria from: Celgene, Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung Bioepis
  • Owns stock, stock options, or bonds from: MedSIR

Disclosure: Sara Hurvitz, MD, FACP, has disclosed the following relevant financial relationships:

  • Received grants for clinical research from: Ambrx; Amgen Inc.; Bayer HealthCare; BI Pharma; BioMarin Pharmaceutical Inc.; Cascadian; Daiichi Sankyo, Inc.; Dignitana; Genentech, Inc.; GlaxoSmithKline; Immunomedics; Lilly; Macrogenics; Medivation; Merrimack; Novartis Pharmaceuticals Corporation; OBI Pharma; Pfizer Inc.; Pieris; PUMA; Radius; Roche; Seattle Genetics
  • Received travel support from: Lilly; Novartis Pharmaceuticals Corporation; OBI Pharma

Disclosure: Sibylle Loibl, MD, PhD, has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: AstraZeneca; Bristol-Myers Squibb Company; Chugai; Daiichi Sankyo, Inc.; Eli Lilly and Company Limited; Merck KGaA; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche; Seattle Genetics
  • Served as a speaker or a member of a speakers bureau for: AstraZeneca; Chugai; Ipsen; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Puma; Roche
  • Received grants for clinical research to institution from: ABCSG; Amgen Inc.; AstraZeneca; Celgene Corporation; Cepheid; Novartis Pharmaceuticals Corporation; NSABP; Pfizer Inc.; Roche
  • Other: Employed–GBG Forschungs gmbH

The employees of prIME, a Medscape Oncology Company have disclosed no relevant financial relationships.

CME/Content Reviewer
Hazel Dennison, DNP, RN, FNP, CPHQ, CNE­  Associate  Director, Accreditation and Compliance
Disclosure: Hazel Dennison,  DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.